Antiplatelet therapy: New foundations for optimal treatment decisions

Neurology

Volumn 53, Issue 7 SUPPL. 4, 1999, Pages

  Albers, Gregory W ^a   Tijssen, Jan G P ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; PLACEBO; STREPTOKINASE; TICLOPIDINE; WARFARIN;

ATHEROSCLEROSIS; BLEEDING; BRAIN EMBOLISM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE FORMULATION; TRANSIENT ISCHEMIC ATTACK;

CEREBROVASCULAR ACCIDENT; DECISION MAKING; HUMANS; NEUROLOGY; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY;

EID: 0032693337     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998;114: 683S-698S.
2. Schrör K. Antiplatelet drugs. A comparative review. Drugs 1995;50:7-28.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
4. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
5. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
6. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054.
7. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
8. Hacke W, Kaste M, Fieschi C, Toni D. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
9. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
10. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349:1641-1649.
11. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
12. EAFT Study Group. The European Atrial Fibrillation Trial. Lancet 1993;342:1244-1262.
13. The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865.
14. Hass WK, Easton JD, Adams HPJ, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321:501-507.
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
16. Bennett CL, Weinberg PD, Brozenberg-Ben-Dror K, Yarnoll PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541-544.
17. Fields WS, Lemak NA, Frankowski R, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-314.
18. Reuther R, Dorndorf W. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions: the results of a double-blind trial. In: Breddin K, Dorndorf W, Loew D, Marx R, eds. Acetylsalicylic acid in cerebral ischemia and coronary heart disease: IV. Colfarit-Symposion Berlin, 30.9.-1.10.1977. Stuttgart: FK Schattauer-Verlag, 1978:97-106.
19. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
20. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires: résultats d'un essai thérapeutique contrôlé de 3 ans. Rev Neurol (Paris) 1982;138:367-385.
21. Bousser MG, Eschwege E, Hagenau M, Lefucconnier JM, Thibult N, Toubooul PJ. "AICLA" controlled trial of aspirin and dypyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;14:5-14.
22. Sorensen PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks: a Danish Cooperative Study. Stroke 1983; 14:15-22.
23. Britton M, Helmer C, Samuelsson K. Swedish Cooperative Study: High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987;18:325-334.
24. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
25. Easton JD. The role of ticlopidine in prevention of ischemic stroke: a benefit-risk assessment. In: Hass WK, Easton JD, eds. Ticlopidine, platelets and vascular disease. New York: Springer-Verlag, 1993:141-155.